Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas, J.N., Zee, B.M., Kalin, J.H., Kim, M., Guo, R., Alexandrescu, S., Blanco, M.A., Giera, S., Gillespie, S.M., Das, J., et al. (2019). Cancer Cell. 36(5), 528-544.
RACK7 recognizes H3.3G34R mutation to suppress expression of MHC class II complex components and their delivery pathway in pediatric glioblastoma.
Jiao, F., Li, Z., He, C., Xu, W., Yang, G., Liu, T, Shen, H., Cai, J., Anastas, J.N., Mao, Y., Yu, Y., Lan, F., Geno, Y., Jones, C., Xu, Y., Baker, S.J.*, Shi, Y.*, Guo, R.*. (2020) Science Advances. 17;6(29):eaba2113. doi: 10.1126/sciadv.aba2113.
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas, J.N., Kulikauskas, R.M., Tamir, T., Rizos, H., Long, G.V., von Euw, E.M., Yang, P.-T., Chen, H.-W., Haydu, L., Toroni, R.A., et al. (2014). J. Clin. Invest. 124(7):2877-90.doi: 10.1172/JCI70156.
A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression.
Anastas, J.N., Biechele, T.L., Robitaille, M., Muster, J., Allison, K.H., Angers, S., and Moon, R.T. (2011). Oncogene. 31(32):3696-708.
WLS inhibits melanoma cell proliferation through the β-catenin signalling pathway and induces spontaneous metastasis.
Yang, P.-T., Anastas, J.N., Toroni, R.A., Shinohara, M.M., Goodson, J.M., Bosserhoff, A.K., Chien, A.J., and Moon, R.T. (2012). EMBO Mol. Med. 4, 1294–1307.
Mindbomb 1, an E3 ubiquitin ligase, forms a complex with RYK to activate Wnt/β-catenin signaling.
Berndt, J.D., Aoyagi, A., Yang, P., Anastas, J.N., Tang, L., and Moon, R.T. (2011). J. Cell Biol. 194, 737–750.
New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening.
Berndt, J.D., Aoyagi, A., Yang, P., Anastas, J.N., Tang, L., and Moon, R.T. (2011). J. Cell Biol. 194, 737–750.
Reviews and Perspectives
Histone Serotonylation: Can the Brain Have “Happy” Chromatin?
Anastas, J.N., and Shi, Y. (2019). Molecular Cell. 74, 418–420.
Histone Lysine Demethylase Inhibitors.
Jambhekar, A., Anastas, J.N., and Shi, Y. (2017). Cold Spring Harb. Perspect. Med. 7.
Functional crosstalk between WNT signaling and tyrosine kinase signaling in cancer.
Anastas, J.N. (2016). Seminars in Oncology, Vol 42, No 6, December 2015, pp 820-831. Semin. Oncol. 43, 526.
WNT signalling pathways as therapeutic targets in cancer.
Anastas, J.N., and Moon, R.T. (2013). Nat. Rev. Cancer 13, 11–26.
